oncology

What’s new in cancer care across Europe in early 2024 (1 Jan – 5 Mar 2024): Advancements, Innovations, Research, Awareness

(IN BRIEF) In early 2024, Europe's medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like…

2 months ago

AstraZeneca Teams Up with Cellectis to Accelerate Gene Therapy Development

(IN BRIEF) AstraZeneca has entered into a collaboration and investment agreement with biotech firm Cellectis to fast-track the development of…

6 months ago

Merck and Hengrui Unite for Pioneering Cancer Therapies Worldwide

(IN BRIEF) Merck, a prominent science and technology company, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals. This…

6 months ago

Servier and Owkin Join Forces to Harness AI for Targeted Therapies in Disease Treatment

(IN BRIEF) Servier, a global pharmaceutical group, has partnered with Owkin, a biotech company specializing in AI-driven drug discovery and…

6 months ago

Merck to Showcase Oncology Portfolio Advancements at ESMO 2023, Highlighting Key Cancer Treatment Breakthroughs

(IN BRIEF) Merck, a leading science and technology company, is set to present 28 abstracts at the 2023 European Society…

6 months ago

Merck Forms AI-Driven Drug Discovery Collaborations with BenevolentAI and Exscientia

(IN BRIEF) Merck, a prominent science and technology company, has announced strategic drug discovery collaborations with AI technology firms BenevolentAI…

7 months ago

AstraZeneca showcases potential of Imfinzi-based treatment for early-stage lung cancer

(IN BRIEF) AstraZeneca will showcase new data from its industry-leading Oncology pipeline and portfolio at the American Association for Cancer…

1 year ago

Sanofi and IGM Biosciences and partner over new class of antibody medicines for the treatment of cancer, immunology, and inflammatory diseases

(PRESS RELEASE) SANOFI, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced…

2 years ago

Tony Wood to succeed Dr Hal Barron as Chief Scientific Officer at GlaxoSmithKline R&D

Tony Wood to assume full accountability for GSK R&D in August 2022 Hal Barron to transition in August 2022 from…

2 years ago

Novartis, Molecular Partners: Ensovibep has the potential to be an important new treatment option in the combat of rapidly evolving SARS-CoV-2 pandemic

Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep,…

2 years ago

EQT further invests in the healthcare sector with the acquisition of Integrated Clinical Oncology Network

EQT Infrastructure has agreed to acquire Icon Group from a consortium including Goldman Sachs Asset Management, QIC and Pagoda. Goldman Sachs…

2 years ago

Prof. Dr. Dominik Ruettinger to lead Research and Early Development for Oncology at Bayer’s Pharmaceuticals Division

(PRESS RELEASE) BERLIN, 26-Jul-2021 — /EuropaWire/ — Bayer, a global enterprise with core competencies in the life science fields of…

3 years ago

EIB signs €15.0 million financing deal with AB Science to support the development of masitinib as a treatment for COVID-19

Financing deal worth €15.0 million signed to support clinical development programme for masitinib Masitinib developed as a credible candidate for treating…

3 years ago

AstraZeneca’s Imfinzi (durvalumab) approved in the US for new four-week 1,500mg fixed-dosing option

(PRESS RELEASE) CAMBRIDGE, 20-Nov-2020 — /EuropaWire/ — AstraZeneca (LON: AZN), a global, science-led biopharmaceutical company, has announced the US Food…

3 years ago

NWO: Spinoza Prize / Stevin Prize, the highest distinction in Dutch Science, awarded to six outstanding researchers

(PRESS RELEASE) THE HAGUE, 19-Jun-2020 — /EuropaWire/ — The Dutch Research Council (NWO) has announced that six researchers will receive…

4 years ago

AstraZeneca: two trials show long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia

ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more…

4 years ago

Liver cancer: Roche’s Tecentriq in combination with Avastin approved by US FDA

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or…

4 years ago

Rare disease: Enhertu of AstraZeneca and Daiichi Sankyo now with Orphan Drug Designation in the US for treatment of gastric cancer

(PRESS RELEASE) CAMBRIDGE, 22-May-2020 — /EuropaWire/ — Enhertu, jointly developed by British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca and the…

4 years ago

University of Zurich researchers announce novel immunotherapy against leukaemia

The new immunotherapy will be tested in humans as soon as possible (PRESS RELEASE) ZURICH, 8-May-2020 — /EuropaWire/ — University…

4 years ago

Brian Tyler to succeed John H. Hammergren as McKesson CEO

San Francisco, CA, USA, 05-Nov-2018 — /EuropaWire/ — McKesson Corporation (NYSE:MCK) today announced that John H. Hammergren, chairman and chief…

5 years ago

Trinity College Dublin to launch a new, free, online course “From Diagnosis to Survivorship: An introduction to Radiation Oncology”

DUBLIN, 30-Aug-2018 — /EuropaWire/ — Trinity is launching a new, free, online course: “From Diagnosis to Survivorship: An introduction to…

6 years ago

Novartis: the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 has met the primary endpoint

SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on…

6 years ago

Royal Philips and Singapore Institute of Advanced Medicine Holdings open Advanced Medicine Imaging (AMI) center at Biopolis research hub in Singapore

First phase of Singapore’s Advanced Medicine Imaging Center provides accurate and timely diagnosis of cancer, plus an education center for…

6 years ago

Novartis: Today’s FDA approval of Kymriah provides another opportunity for Novartis to build on its leadership in CAR-T development

Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of…

6 years ago

KTH Professor of Experimental Oncology Cecilia Williams: beta receptor’s discovery changed our understanding of estrogen signaling

STOCKHOLM, 16-Jun-2017 — /EuropaWire/ — For nearly two decades researchers have sought a way to target an estrogen receptor in…

7 years ago

Royal Philips, Memorial Sloan Kettering Cancer Center to help improve the understanding of pancreatic cancer and advance precision oncology

Agreement aims to enable precision diagnostics for pancreatic cancer by developing new methods* to resolve single-cell level differences within and…

7 years ago

Novartis third annual Meet Novartis Management event in Basel: Leading positions in oncology, eye care and biosimilars

Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong…

8 years ago

Basilea announced improved operating results in its H1-2013 financials

Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data…

11 years ago

AstraZeneca, University of Cambridge and Cancer Research UK partner on 3 pre-clinical and clinical oncology projects

16-7-2013 — /europawire.eu/ — AstraZeneca today announced that it has entered into an agreement with the University of Cambridge and Cancer…

11 years ago

SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® results announced by AstraZeneca and Bristol-Myers Squibb

20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular…

11 years ago